AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31846558 — intervention group
Group type: COMPARATOR
Intervention: 2D HD endoscopy
Number of subjects: 30
Study 30786095 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient‐Oriented Safe Transition programme (individual discharge planning by case managers, home visits by homecare nurses, telephone calls for one month)
Number of subjects: 83
Study 30786095 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient‐Oriented Safe Transition programme
Number of subjects: 83
Study 30786095 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard discharge process)
Number of subjects: 83
Study 28969890 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri strain DSM 17938 (5 × 10^8 colony-forming units daily)
Number of subjects: 20
Study 28969890 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sunflower oil)
Number of subjects: 20
Study 26159012 — intervention group
Group type: EXPERIMENTAL
Intervention: Danlong Oral Liquid (DOL), 10 mL each time, 3 times per day for 7 days
Number of subjects: 480
Study 26159012 — intervention group
Group type: COMPARATOR
Intervention: Kechuanning Oral Liquid (KOL), 10 mL each time, 3 times per day for 7 days
Number of subjects: 480
Study 23265179 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Navigation System (LNS)
Number of subjects: 58
Study 23265179 — intervention group
Group type: COMPARATOR
Intervention: Conventional freehand procedure
Number of subjects: 58
Study 21982673 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral informed consent
Number of subjects: 63
Study 21982673 — intervention group
Group type: EXPERIMENTAL
Intervention: Written informed consent
Number of subjects: 63
Study 21982673 — intervention group
Group type: EXPERIMENTAL
Intervention: Video informed consent
Number of subjects: 63
Study 21982673 — intervention group
Group type: COMPARATOR
Intervention: All formats (oral, written, video)
Number of subjects: 63
Study 19356104 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (n=5)
Number of subjects: 66
Study 19356104 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (n=9)
Number of subjects: 66
Study 19356104 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=52)
Number of subjects: 66
Study 19356104 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine/Efavirenz treatment (follow-up patients)
Number of subjects: 66
Study 19356104 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (non-compliance)
Number of subjects: 66
Study 17069471 — intervention group
Group type: EXPERIMENTAL
Intervention: RS‐86 (M1 mAChR agonist)
Number of subjects: 20
Study 17069471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15234410 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 512
Study 15234410 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to reinstitute CRT
Number of subjects: 512
Study 15234410 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial tachyarrhythmias
Number of subjects: 512
Study 10971822 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) therapy
Number of subjects: 998
Study 8624772 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil treatment
Number of subjects: 21
Study 8624772 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 21
Study 1379907 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 0
Study 6378233 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg twice daily
Number of subjects: 0
Study 6378233 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac 200 mg twice daily
Number of subjects: 0
Study 3742936 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam, 0.5 mg
Number of subjects: 48
Study 3742936 — intervention group
Group type: COMPARATOR
Intervention: Triazolam, 0.25 mg
Number of subjects: 48
Study 3742936 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam (dose not specified)
Number of subjects: 48
Study 3742936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 28669575 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted Interdisciplinary Model for Evaluation and Treatment of Neuropsychiatric Symptoms (TIME)
Number of subjects: 229
Study 28669575 — intervention group
Group type: COMPARATOR
Intervention: Brief education-only intervention (Control)
Number of subjects: 229
Study 27555884 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthèse Diabète (new removable off‐loading orthosis)
Number of subjects: 117
Study 27555884 — intervention group
Group type: COMPARATOR
Intervention: Control group (any removable device)
Number of subjects: 117
Study 24983776 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian artery velocimetry in women with spontaneous LH surge
Number of subjects: 130
Study 24983776 — intervention group
Group type: COMPARATOR
Intervention: Ovarian artery velocimetry in women needing HCG administration
Number of subjects: 130
Study 23340148 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-conducted medication review
Number of subjects: 69
Study 23340148 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 69
Study 20730517 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated smoking cessation and binge-drinking intervention (n=22)
Number of subjects: 41
Study 20730517 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (n=19)
Number of subjects: 41
Study 18515954 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 18515954 — intervention group
Group type: COMPARATOR
Intervention: Bisphosphonates
Number of subjects: 0
Study 16181532 — intervention group
Group type: EXPERIMENTAL
Intervention: Astragalus injection (AI)
Number of subjects: 72
Study 16181532 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 72
Study 14668131 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention system for periodontal health
Number of subjects: 13
Study 14668131 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face toothbrushing instruction and follow-up via telephone (Control)
Number of subjects: 13
Study 10534247 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 U BoNT/B (NeuroBloc) administered in a single session into two to four clinically involved muscles.
Number of subjects: 77
Study 10534247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 10534247 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 U BoNT/B (NeuroBloc)
Number of subjects: 77
Study 8758013 — intervention group
Group type: EXPERIMENTAL
Intervention: Wu Chian‐Ch'uan style Tai Chi
Number of subjects: 126
Study 8758013 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 126
Study 8758013 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise support group
Number of subjects: 126
Study 1748849 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent tutoring system designed using the developed methodology
Number of subjects: 0
Study 6578788 — intervention group
Group type: EXPERIMENTAL
Intervention: Community treatment with comprehensive support and a 24-hour crisis service
Number of subjects: 120
Study 6578788 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital care and after-care (Control)
Number of subjects: 120
Study 31806021 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized moderate-intensity endurance training for 6 weeks
Number of subjects: 16
Study 29941991 — intervention group
Group type: EXPERIMENTAL
Intervention: IP6 supplements for 3 months
Number of subjects: 33
Study 26211605 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocalciferol (vitamin D2) 50,000 IU twice weekly for 8 weeks
Number of subjects: 47
Study 26211605 — intervention group
Group type: COMPARATOR
Intervention: Cholecalciferol (vitamin D3) 50,000 IU weekly for 8 weeks
Number of subjects: 47
Study 25294376 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative cognitive dysfunction (POCD) group
Number of subjects: 50
Study 25294376 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum percentage drop in regional cerebral oxygen saturation (rSO2)
Number of subjects: 50
Study 25294376 — intervention group
Group type: EXPERIMENTAL
Intervention: rSO(2, %max) value
Number of subjects: 50
Study 25294376 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Aβ levels after 24 h in POCD group
Number of subjects: 50
Study 25294376 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Aβ levels after 24 h in POCD group vs non-POCD group
Number of subjects: 50
Study 22524975 — intervention group
Group type: EXPERIMENTAL
Intervention: High lysine diet (80 mgkg(‐1)d(‐1))
Number of subjects: 40
Study 22524975 — intervention group
Group type: COMPARATOR
Intervention: Low lysine diet (∼25 mgkg(‐1)d(‐1) for under-nourished and ∼40 mgkg(‐1)d(‐1) for well-nourished)
Number of subjects: 40
Study 19158237 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity program
Number of subjects: 0
Study 19158237 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary modification program
Number of subjects: 0
Study 19158237 — intervention group
Group type: EXPERIMENTAL
Intervention: Both physical activity and dietary modification programs
Number of subjects: 0
Study 19158237 — intervention group
Group type: EXPERIMENTAL
Intervention: Home activities
Number of subjects: 0
Study 17268068 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506 (Tacrolimus); dosage and duration not specified
Number of subjects: 28
Study 17268068 — intervention group
Group type: COMPARATOR
Intervention: Control group (MG(FK-)); no FK506 administration
Number of subjects: 28
Study 17268068 — intervention group
Group type: COMPARATOR
Intervention: Control group (Healthy subjects); no FK506 administration
Number of subjects: 28
Study 16119511 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of cefepime 4 g/d
Number of subjects: 50
Study 16119511 — intervention group
Group type: COMPARATOR
Intervention: Intermittent administration of cefepime 2 x 2 g
Number of subjects: 50
Study 11368700 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (distal chevron osteotomy)
Number of subjects: 209
Study 11368700 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthosis
Number of subjects: 209
Study 11368700 — intervention group
Group type: COMPARATOR
Intervention: Control (1-year waiting list)
Number of subjects: 209
Study 9385488 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg QD
Number of subjects: 29
Study 9385488 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole 15 mg QD
Number of subjects: 29
Study 9385488 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg QD
Number of subjects: 29
Study 9385488 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 150 mg QID
Number of subjects: 29
Study 8187316 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (Group 1)
Number of subjects: 34
Study 8187316 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg three times daily (Group 2)
Number of subjects: 34
Study 8187316 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg three times daily (Group 3)
Number of subjects: 34
Study 3108170 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate (900-1,200 mg/day for 4 days)
Number of subjects: 28
Study 3108170 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 28
Study 30395486 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atomoxetine plus 5 mg oxybutynin (ato-oxy)
Number of subjects: 20
Study 30395486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30395486 — intervention group
Group type: COMPARATOR
Intervention: 80 mg atomoxetine
Number of subjects: 20
Study 30395486 — intervention group
Group type: COMPARATOR
Intervention: 5 mg oxybutynin
Number of subjects: 20
Study 26790987 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer-Related Symptoms
Number of subjects: 1138
Study 26790987 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Impairment
Number of subjects: 1138
Study 26790987 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer-Related Symptoms mediated by Functional Impairment
Number of subjects: 1138
Study 25795507 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-site biventricular pacing
Number of subjects: 120
Study 25795507 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-site biventricular pacing
Number of subjects: 120
Study 25795507 — intervention group
Group type: COMPARATOR
Intervention: Nonimplanted control group
Number of subjects: 120
Study 25795507 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing intervention (both dual-site and single-site)
Number of subjects: 120
Study 24490418 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education + protective skill training
Number of subjects: 0
Study 24490418 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 0
Study 21293249 — intervention group
Group type: COMPARATOR
Intervention: Losartan (n = 30)
Number of subjects: 99
Study 21293249 — intervention group
Group type: COMPARATOR
Intervention: Mizoribine (n = 35)
Number of subjects: 99
Study 21293249 — intervention group
Group type: COMPARATOR
Intervention: Combination of losartan and mizoribine (n = 34)
Number of subjects: 99
Study 19878577 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD) stage 3
Number of subjects: 3117
Study 19878577 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD) stage 4
Number of subjects: 3117
Study 19878577 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD) stage 5
Number of subjects: 3117
Study 19878577 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with CKD (stage 3-5)
Number of subjects: 3117
Study 19878577 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension as a cardiovascular risk factor
Number of subjects: 3117
Study 19878577 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes as a cardiovascular risk factor
Number of subjects: 3117
Study 19878577 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographical region (northeast vs central)
Number of subjects: 3117
Study 16717306 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 2 mg/kg
Number of subjects: 40
Study 16717306 — intervention group
Group type: COMPARATOR
Intervention: Morphine 0.2 mg/kg
Number of subjects: 40
Study 14687095 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1.0 micro g.kg‐1
Number of subjects: 112
Study 14687095 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 2.0 micro g.kg‐1
Number of subjects: 112
Study 14687095 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 3.0 micro g.kg‐1
Number of subjects: 112
Study 14687095 — intervention group
Group type: COMPARATOR
Intervention: Control (Propofol and Mivacurium 0.2 mg.kg‐1)
Number of subjects: 112
Study 14687095 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil 1.0 micro g.kg‐1 and Control
Number of subjects: 112
Study 11352853 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg once daily for 28 days
Number of subjects: 92
Study 9205820 — intervention group
Group type: EXPERIMENTAL
Intervention: Draflazine 0.25 mg
Number of subjects: 0
Study 9205820 — intervention group
Group type: EXPERIMENTAL
Intervention: Draflazine 0.5 mg
Number of subjects: 0
Study 9205820 — intervention group
Group type: EXPERIMENTAL
Intervention: Draflazine 1 mg
Number of subjects: 0
Study 9205820 — intervention group
Group type: EXPERIMENTAL
Intervention: Draflazine 1.5 mg
Number of subjects: 0
Study 9205820 — intervention group
Group type: EXPERIMENTAL
Intervention: Draflazine 2.5 mg
Number of subjects: 0
Study 9205820 — intervention group
Group type: EXPERIMENTAL
Intervention: Draflazine 1 mg followed by 1 mg h‐1 infusion
Number of subjects: 0
Study 8025138 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial revascularization (surgical therapy)
Number of subjects: 0
Study 8025138 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous intervention
Number of subjects: 0
Study 8025138 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 0
Study 2821938 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 16
Study 29562405 — intervention group
Group type: EXPERIMENTAL
Intervention: Penehyclidine hydrochloride 0.05 mg/kg
Number of subjects: 60
Study 29562405 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline
Number of subjects: 60
Study 27600995 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine + erlotinib (G + E)
Number of subjects: 285
Study 27600995 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine + placebo (G + P)
Number of subjects: 285
Study 26324753 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on scanning with fetal pig simulation
Number of subjects: 24
Study 26324753 — intervention group
Group type: COMPARATOR
Intervention: Hands-on scanning with pregnant women
Number of subjects: 24
Study 23425543 — intervention group
Group type: EXPERIMENTAL
Intervention: In-patient complete multivessel PCI
Number of subjects: 300
Study 23425543 — intervention group
Group type: COMPARATOR
Intervention: Culprit (IRA)-only PCI
Number of subjects: 300
Study 21274861 — intervention group
Group type: EXPERIMENTAL
Intervention: ITPA variants (rs1127354 and rs7270101)
Number of subjects: 238
Study 21274861 — intervention group
Group type: EXPERIMENTAL
Intervention: ITPase deficiency variable (combined ITPA variants)
Number of subjects: 238
Study 21274861 — intervention group
Group type: EXPERIMENTAL
Intervention: ITPase deficiency
Number of subjects: 238
Study 21274861 — intervention group
Group type: EXPERIMENTAL
Intervention: ITPA variants
Number of subjects: 238
Study 19097805 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient bland embolization or chemoembolization
Number of subjects: 77
Study 16510639 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 372
Study 16510639 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 372
Study 16510639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 15241611 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% once daily
Number of subjects: 61
Study 15241611 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% and Latanoprost 0.005%
Number of subjects: 61
Study 11018852 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine/didanosine/nevirapine
Number of subjects: 0
Study 11018852 — intervention group
Group type: COMPARATOR
Intervention: zidovudine/didanosine
Number of subjects: 0
Study 7714940 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltamethrin impregnated nets
Number of subjects: 1700
Study 7714940 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated nets
Number of subjects: 1700
Study 7714940 — intervention group
Group type: COMPARATOR
Intervention: Untreated control villages
Number of subjects: 1700
Study 2750573 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-Meal
Number of subjects: 7
Study 2750573 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal-Exercise
Number of subjects: 7
Study 2750573 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Only
Number of subjects: 7
Study 2750573 — intervention group
Group type: COMPARATOR
Intervention: Meal Only
Number of subjects: 7
Study 1277437 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 140
Study 1277437 — intervention group
Group type: EXPERIMENTAL
Intervention: Tartrazine
Number of subjects: 140
Study 1277437 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) and Tartrazine
Number of subjects: 140
Study 1277437 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 140
Study 31912523 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified hydrophilic sandblasted and acid‐etched neck (mSLA; test)
Number of subjects: 43
Study 31912523 — intervention group
Group type: COMPARATOR
Intervention: Machined neck (M; control)
Number of subjects: 43
Study 31521131 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretical lecture
Number of subjects: 48
Study 31521131 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretical lecture with training on anatomical models
Number of subjects: 48
Study 31521131 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretical lecture with training on cadavers
Number of subjects: 48
Study 29025788 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation intervention (8-week, 10-15 minutes, three times a week during hemodialysis)
Number of subjects: 41
Study 29025788 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (control group)
Number of subjects: 41
Study 24652887 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 440
Study 25302067 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianjiu therapy for 1 year
Number of subjects: 102
Study 25302067 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianjiu therapy for 2 years
Number of subjects: 102
Study 22750124 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional switching
Number of subjects: 0
Study 22750124 — intervention group
Group type: EXPERIMENTAL
Intervention: Response conflict
Number of subjects: 0
Study 22750124 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional connectivity between dACC and inferior temporal cortex
Number of subjects: 0
Study 22750124 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional connectivity between dACC and posterior parietal cortex
Number of subjects: 0
Study 19640960 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3175
Study 19640960 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Number of subjects: 3175
Study 19640960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3175
Study 17208602 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg oral immunotherapy (OIT)
Number of subjects: 7
Study 15642674 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood stem cell (BSC) allografts
Number of subjects: 0
Study 15642674 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow (BM) allografts
Number of subjects: 0
Study 15642674 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with extensive chronic GVHD
Number of subjects: 0